Markets:

Overview

News

Currencies

International

Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

166.09 -3.60 (-2.12%)

Streaming Delayed Price Updated: 1:32 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year

May 05, 2022

From Insulet Corporation

Via Business Wire

Insulet’s 2021 Sustainability Report Reveals Progress on Strategy to Deliver Growth with Purpose

May 02, 2022

From Insulet Corporation

Via Business Wire

Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes ↗

April 27, 2022

Insulet Corporation (NASDAQ: PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with...

Via Benzinga

Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes

April 27, 2022

From Insulet Corporation

Via Business Wire

Expert Ratings For Insulet ↗

January 31, 2022

Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:

Via Benzinga

Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022

April 07, 2022

From Insulet Corporation

Via Business Wire

Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20% ↗

February 24, 2022

Insulet Corp's (NASDAQ: PODD) Q4 FY21 revenue increased 25% (25.7% in constant currency) to $307.7 million, exceeding the consensus of $301.06 million. The company...

Via Benzinga

Recap: Insulet Q4 Earnings ↗

February 23, 2022

Insulet (NASDAQ:PODD) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet...

Via Benzinga

Insulet Reports Full Year 2021 Revenue Increase of 21% and Fourth Quarter 2021 Revenue Increase of 25% Year-Over-Year

February 23, 2022

From Insulet Corporation

Via Business Wire

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗

February 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Earnings Scheduled For February 23, 2022 ↗

February 23, 2022

Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)...

Via Benzinga

Insulet Promotes Inclusivity for People with Diabetes through Nintendo® Video Game Animal Crossing™: New Horizons

February 17, 2022

From Insulet Corporation

Via Business Wire

Insulet to Present at Upcoming Investor Conferences

February 16, 2022

From Insulet Corporation

Via Business Wire

Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine

February 07, 2022

From Insulet Corporation

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022 ↗

February 03, 2022

Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 28, 2022

Gainers Provention Bio (NASDAQ:PRVB) stoc...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022 ↗

February 02, 2022

Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09...

Via Benzinga

FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients Aged 6 Years & Above ↗

January 28, 2022

The

Via Benzinga

Mid-Day Market Update: US Stocks Turn Positive; Nasdaq Surges 2% ↗

January 28, 2022

US stocks turned higher, with all the three major indices recording gains. The Nasdaq climbed more than 2% following stronger-than-expected earnings results from Apple Inc. (...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗

January 31, 2022

Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...

Via Benzinga

33 Stocks Moving In Friday's Mid-Day Session ↗

January 28, 2022

Gainers Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 126% to $2.6219. Imperial Petroleum, last month, posted Q3 revenue of $4.1 million. Yoshitsu Co., Ltd (NASDAQ: TKLF...

Via Benzinga

52 Biggest Movers From Friday ↗

January 31, 2022

Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share. Imperial Petroleum Inc. (NASDAQ:...

Via Benzinga

Benzinga Pro's Top 5 Stocks To Watch For Friday, Jan. 28, 2022: PODD, KR, TEAM, GOOGL, SBUX ↗

January 28, 2022

Today's 5 Stock Ideas: Insulet (PODD) - Shares up premarket. The company announced FDA clearance of its Omnipod 5 Automated Insulin Delivery System. Kroger (KR) - Shares...

Via Benzinga

Insulet Announces FDA Clearance of its Omnipod® 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control

January 28, 2022

From Insulet Corporation

Via Business Wire

If You Invested $100 In This Stock 5 Years Ago, Here's How Much You Would Have Today ↗

January 13, 2022

Insulet (NASDAQ:PODD) has outperformed the market over the past 5 years by 24.86% on an annualized basis. Buying $100 In PODD: 5 years ago, an investor could have purchased 2.30...

Via Benzinga

This Foreboding Sign Looms Over Insulet's Chart ↗

January 13, 2022

If history is any guide, there may be trouble ahead for shares of Insulet (NASDAQ:PODD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...

Via Benzinga

CORRECTING and REPLACING Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

January 12, 2022

From Insulet Corporation

Via Business Wire

Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2021

January 12, 2022

From Insulet Corporation

Via Business Wire

Insulet to Present at Nasdaq’s 45th Investor Conference

November 24, 2021

From Insulet Corporation

Via Business Wire

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.